A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01017952
First received: November 19, 2009
Last updated: August 15, 2013
Last verified: August 2013
  Purpose

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: FF/GW642444 Inhalation Powder
Drug: GW642444 Inhalation Powder
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean [ Time Frame: From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.


Secondary Outcome Measures:
  • Time to First Occurrence of Moderate or Severe COPD Exacerbation [ Time Frame: From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.

  • Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean [ Time Frame: From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.

  • Change From Baseline in Trough FEV1 at Week 52 (Visit 11) [ Time Frame: Baseline to Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.


Enrollment: 1635
Study Start Date: September 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FF/GW642444 Inhalation Powder 100/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: FF/GW642444 Inhalation Powder 50mcg/25mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: FF/GW642444 Inhalation Powder 200/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: GW642444 25mcg QD
Long Acting Beta Agonist(LABA)
Drug: GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type of subject: outpatient
  • Informed consent: Subjects must give their signed and dated written informed consent to participate.
  • Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH > 40MIU/ml and estradiol <40pg/ml (<140 pmol/L) is confirmatory. OR

Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):

  • Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
  • Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
  • Implants of levonorgestral inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
  • Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
  • Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
  • Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
  • An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
  • Estrogenic vaginal ring; or
  • Percutaneous contraceptive patches

    • Age: ≥40 years of age at Screening (Visit 1)
    • COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
    • Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. Number of pack years = (number of cigarettes per day/20) x number of years smoked
    • Severity of Disease:
  • Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)
  • Subjects with a measured post-albuterol/salbutamol FEV1 <70% of predicted normal values calculated (via centralized vendor equipment) using NHANES III reference equations [Hankinson, 1999] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber. The study provided central spirometry equipment will calculate the FEV1/FVC ratio and FEV1 percent predicted values.

    • History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
  • α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
  • Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
  • Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit 1), the subject will not be eligible for the study.
  • Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's, Myasthenia Gravis, etc).
  • A moderate and severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
  • Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue in the study, but may be re-screened at a later time provided the pneumonia and/or COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit must be conducted at least ≥ 14 days following the resolution date of the exacerbation and/or pneumonia and at least 30 days following the last dose of oral corticosteroids (if applicable).
  • Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.
  • Hypertension: Subjects with clinically significant hypertension that is uncontrolled.
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
  • Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to spirometry testing at each study visit.
  • Additional medication: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.
  • Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
  • Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
  • Prior use of study medication/other investigational drugs: Subjects who have previously been randomized to treatment with GW642444 Inhalation Powder in the B2C111045 study, randomized to treatment in the HZC111348 study or have participated in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer.
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01017952

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35215
GSK Investigational Site
Birmingham, Alabama, United States, 35294
GSK Investigational Site
Mobile, Alabama, United States, 36608
GSK Investigational Site
Ozark, Alabama, United States, 36360
GSK Investigational Site
Tallassee, Alabama, United States, 36078
United States, Arizona
GSK Investigational Site
Chandler, Arizona, United States, 85224
GSK Investigational Site
Peoria, Arizona, United States, 85381 - 4828
GSK Investigational Site
Phoenix, Arizona, United States, 85012
GSK Investigational Site
Tucson, Arizona, United States, 85723
United States, California
GSK Investigational Site
Fresno, California, United States, 93710
GSK Investigational Site
Fresno, California, United States, 93726
GSK Investigational Site
Long Beach, California, United States, 90808
GSK Investigational Site
Monterey Park, California, United States, 91754
GSK Investigational Site
National City, California, United States, 91950
GSK Investigational Site
San Diego, California, United States, 92117
GSK Investigational Site
San Diego, California, United States, 92128
GSK Investigational Site
Torrance, California, United States, 90502
GSK Investigational Site
Torrance, California, United States, 90505
GSK Investigational Site
Van Nuys, California, United States, 91405
United States, Colorado
GSK Investigational Site
Boulder, Colorado, United States, 80304
GSK Investigational Site
Thornton, Colorado, United States, 80233
United States, Connecticut
GSK Investigational Site
Hartford, Connecticut, United States, 06105
United States, Florida
GSK Investigational Site
Clearwater, Florida, United States, 33765
GSK Investigational Site
Cocoa, Florida, United States, 32927
GSK Investigational Site
Deland, Florida, United States, 32720
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33316
GSK Investigational Site
Kissimmee, Florida, United States, 34741
GSK Investigational Site
Miami, Florida, United States, 33183
GSK Investigational Site
Pensacola, Florida, United States, 32503
GSK Investigational Site
St. Petersburg, Florida, United States, 33707
GSK Investigational Site
Tampa, Florida, United States, 33603
GSK Investigational Site
Winter Park, Florida, United States, 32789
United States, Georgia
GSK Investigational Site
Gainesville, Georgia, United States
GSK Investigational Site
Martinez, Georgia, United States, 30907
GSK Investigational Site
Riverdale, Georgia, United States, 30274
United States, Idaho
GSK Investigational Site
Coeur D'Alene, Idaho, United States, 83814
United States, Illinois
GSK Investigational Site
Aurora, Illinois, United States, 60504
GSK Investigational Site
Elk Grove Village, Illinois, United States, 60007
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Evansville, Indiana, United States, 47713
United States, Iowa
GSK Investigational Site
Council Bluffs, Iowa, United States, 51503
United States, Kansas
GSK Investigational Site
Olathe, Kansas, United States, 66061
GSK Investigational Site
Topeka, Kansas, United States, 66606
United States, Kentucky
GSK Investigational Site
Hazard, Kentucky, United States, 41701
GSK Investigational Site
Madisonville, Kentucky, United States, 42431
United States, Massachusetts
GSK Investigational Site
Brockton, Massachusetts, United States, 02301
GSK Investigational Site
Fall River, Massachusetts, United States, 02720
GSK Investigational Site
Pittsfield, Massachusetts, United States, 01201
United States, Michigan
GSK Investigational Site
Cadillac, Michigan, United States, 49601
United States, Minnesota
GSK Investigational Site
Edina, Minnesota, United States, 55438
GSK Investigational Site
Fridley, Minnesota, United States, 55432
United States, Missouri
GSK Investigational Site
Columbia, Missouri, United States, 65212
GSK Investigational Site
Springfield, Missouri, United States, 65803
GSK Investigational Site
St. Louis, Missouri, United States, 63141
GSK Investigational Site
St. Louis, Missouri, United States, 63143
United States, Nebraska
GSK Investigational Site
Lincoln, Nebraska, United States, 68506
GSK Investigational Site
Omaha, Nebraska, United States, 68134
GSK Investigational Site
Papillion, Nebraska, United States, 68046
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
United States, New Jersey
GSK Investigational Site
Cherry Hill, New Jersey, United States, 08003
GSK Investigational Site
Summit, New Jersey, United States, 07091
United States, New York
GSK Investigational Site
Albany, New York, United States, 12205
GSK Investigational Site
North Syracuse, New York, United States, 13212
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28803
GSK Investigational Site
Burlington, North Carolina, United States, 27215
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
GSK Investigational Site
Statesville, North Carolina, United States, 28625
GSK Investigational Site
Wilmington, North Carolina, United States, 28401
United States, Ohio
GSK Investigational Site
Centerville, Ohio, United States, 45459
GSK Investigational Site
Toledo, Ohio, United States, 43614
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97220
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29406
GSK Investigational Site
Columbia, South Carolina, United States, 29201
GSK Investigational Site
Easley, South Carolina, United States, 29640
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Murrells Inlet, South Carolina, United States, 29576
GSK Investigational Site
Pelzer, South Carolina, United States, 29669
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
GSK Investigational Site
Corsicana, Texas, United States, 75110
GSK Investigational Site
Dallas, Texas, United States, 75231
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
New Braunfels, Texas, United States, 78130
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
Wichita Falls, Texas, United States, 76309
United States, Virginia
GSK Investigational Site
Newport News, Virginia, United States, 23606
GSK Investigational Site
Richmond, Virginia, United States, 23249
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53715
Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
GSK Investigational Site
Mendoza, Argentina, M5500CCG
GSK Investigational Site
Tucuman, Argentina, 4000
GSK Investigational Site
Tucumán, Argentina, T4000DGF
Australia, New South Wales
GSK Investigational Site
Kingswood, New South Wales, Australia, 2747
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
GSK Investigational Site
Auchenflower, Queensland, Australia, 4066
GSK Investigational Site
Southport, Queensland, Australia, 4215
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Tasmania
GSK Investigational Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
GSK Investigational Site
Box Hill, Victoria, Australia, 3128
Australia, Western Australia
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2K 3S8
Canada, Nova Scotia
GSK Investigational Site
Truro, Nova Scotia, Canada, B2N 1L2
Canada, Ontario
GSK Investigational Site
Grimsby, Ontario, Canada, L3M 1P3
GSK Investigational Site
Hamilton, Ontario, Canada, L8M 1K7
GSK Investigational Site
London, Ontario, Canada, N5W 6A2
GSK Investigational Site
Newmarket, Ontario, Canada, L3Y 5G8
GSK Investigational Site
Sarnia, Ontario, Canada, N7T 4X3
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1N8
Canada, Quebec
GSK Investigational Site
Gatineau, Quebec, Canada, J8Y 6S8
GSK Investigational Site
Mirabel, Quebec, Canada, J7J 2K8
GSK Investigational Site
Montreal, Quebec, Canada, H2X 2P4
Chile
GSK Investigational Site
Puente Alto - Santiago, Región Metro De Santiago, Chile, 8207257
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500691
GSK Investigational Site
Talcahuano, Chile, 4270918
Denmark
GSK Investigational Site
Aalborg, Denmark, 9100
GSK Investigational Site
Aarhus C, Denmark, 8000
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
Kobenhavn NV, Denmark, 2400
GSK Investigational Site
Odense C, Denmark, 5000
Germany
GSK Investigational Site
Frankfurt, Hessen, Germany, 60596
GSK Investigational Site
Kassel, Hessen, Germany, 34121
GSK Investigational Site
Marburg, Hessen, Germany, 35037
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65183
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30167
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45359
GSK Investigational Site
Hamburg, Germany, 20354
Italy
GSK Investigational Site
Salerno, Campania, Italy, 84100
GSK Investigational Site
San Felice a Cancello Caserta, Campania, Italy, 81027
GSK Investigational Site
Modena, Emilia-Romagna, Italy, 41124
GSK Investigational Site
Parma, Emilia-Romagna, Italy, 43100
GSK Investigational Site
Roma, Lazio, Italy, 00168
GSK Investigational Site
Foggia, Puglia, Italy, 71100
GSK Investigational Site
Palermo, Sicilia, Italy, 90146
GSK Investigational Site
Pisa, Toscana, Italy, 56124
GSK Investigational Site
Perugia, Umbria, Italy, 06156
Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico, 44600
GSK Investigational Site
Zapopan, Jalisco, Mexico, 45040
GSK Investigational Site
Monterrey, Nuevo León, Mexico, 64460
Netherlands
GSK Investigational Site
Almelo, Netherlands, 7609 PP
GSK Investigational Site
Almere, Netherlands, 1315 RA
GSK Investigational Site
Beek, Netherlands, 6191 JW
GSK Investigational Site
Breda, Netherlands, 4819 EV
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Groningen, Netherlands, 9728 NP
GSK Investigational Site
Hoorn, Netherlands, 1624 NP
GSK Investigational Site
Horn, Netherlands, 6085 NM
GSK Investigational Site
Nieuwegein, Netherlands, 3435 CM
GSK Investigational Site
Zutphen, Netherlands, 7207 AE
Peru
GSK Investigational Site
Lima 18, Lima, Peru
GSK Investigational Site
San Miguel, Lima, Peru, Lima 32
GSK Investigational Site
Santiago de Surco, Lima, Peru, Lima 33
GSK Investigational Site
Callao, Peru, Callao 2
South Africa
GSK Investigational Site
Meyerspark, Gauteng, South Africa, 0184
GSK Investigational Site
Parktown, Gauteng, South Africa, 2193
GSK Investigational Site
Waterkloof Ridge, Gauteng, South Africa, 0181
GSK Investigational Site
Bellville, South Africa, 7530
GSK Investigational Site
Bloemfontein, South Africa, 9301
GSK Investigational Site
Cape Town, South Africa, 7572
GSK Investigational Site
Gatesville, South Africa, 7764
GSK Investigational Site
Mowbray, South Africa, 7700
GSK Investigational Site
Roodepoort, South Africa, 1724
GSK Investigational Site
Worcester, South Africa, 6850
Spain
GSK Investigational Site
Alicante, Spain, 03114
GSK Investigational Site
Cartagena (Murcia), Spain, 30202
GSK Investigational Site
Cáceres, Spain, 10003
GSK Investigational Site
Elda, Spain, 03600
GSK Investigational Site
Galdakano, Spain, 48960
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Orihuela/Alicante, Spain, 03314
GSK Investigational Site
Pama de Mallorca, Spain, 07010
GSK Investigational Site
Pozuelo de Alarcón/Madrid, Spain, 28223
Sweden
GSK Investigational Site
Bankeryd, Sweden, SE-564 31
GSK Investigational Site
Karlskrona, Sweden, SE-371 41
GSK Investigational Site
Lidingö, Sweden, SE-181 58
GSK Investigational Site
Åtvidaberg, Sweden, SE-597 26
United Kingdom
GSK Investigational Site
Southampton, Hampshire, United Kingdom, SO16 6YD
GSK Investigational Site
Bradford on Avon, Wiltshire, United Kingdom, BA15 1DQ
GSK Investigational Site
Trowbridge, Wiltshire, United Kingdom, BA14 8QA
GSK Investigational Site
Cambridge, United Kingdom, CB2 0QQ
GSK Investigational Site
Chertsey, Surrey, United Kingdom, KT16 0PZ
GSK Investigational Site
Wythenshawe, Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01017952     History of Changes
Other Study ID Numbers: 102970
Study First Received: November 19, 2009
Results First Received: May 30, 2013
Last Updated: August 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Safety
COPD
FEV1
Efficacy

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Fluticasone
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Dermatologic Agents
Anti-Allergic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on July 22, 2014